Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_assertion type Assertion NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_head.
- NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_assertion description "[A phase II trial is ongoing to test the hypothesis that a compound, high-dose medroxyprogesterone acetate (MPA), used as an unconventional gluocorticoid, will stimulate breast cancer cells to reexpress Nm23-H1 and limit subsequent metastatic colonization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_provenance.
- NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_assertion evidence source_evidence_literature NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_provenance.
- NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_assertion SIO_000772 18698018 NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_provenance.
- NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_assertion wasDerivedFrom befree-20150227 NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_provenance.
- NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_assertion wasGeneratedBy ECO_0000203 NP592203.RAd85dfeq24-iPTgK9wEbHGLRtQe2AUS_8aDG0Su04K28130_provenance.